Form 4 for WGS GeneDx Holdings Corp.
Accepted 2025-01-31 00:00:00 ET · period of report 2025-01-29 · accession 0001415889-25-002534 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-01-31 | 2025-01-29 | WGS | Stueland Katherine | CEO, Dir | M - OptEx | $0.00 | +3,874 | 5,594 | +225% | $0 |
| D | 2025-01-31 | 2025-01-29 | WGS | Stueland Katherine | CEO, Dir | S - Sale+OE | $78.48 | -1,657 | 3,937 | -30% | -$130.0K |
| D | 2025-01-31 | 2025-01-29 | WGS | Stueland Katherine | CEO, Dir | M - OptEx | $0.00 | -3,874 | 19.4K | -17% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Class A Common Stock | 2025-01-29 | M | A | 3,874 | $0.00 | 5,594 | D | — | — | (F1) Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. |
| 2 | Common | Class A Common Stock | 2025-01-29 | S | D | 1,657 | $78.48 | 3,937 | D | — | — | (F3) The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $78.48 to $79.0497 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| 3 | Derivative | Restricted Stock Unit | 2025-01-29 | M | D | 3,874 | $0.00 | 19,370 | D | — · — to — | 3,874 Class A Common Stock | (F1) Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. (F4) 25% of the underlying shares each vested on April 29, 2023 and April 29, 2024, and 6.25% vest in quarterly installments thereafter until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date. |